IL141627A0 - Activation and protection of t-cells (cd4+and cd8+) using an h2 receptor agonist and other t-cell activating agents - Google Patents

Activation and protection of t-cells (cd4+and cd8+) using an h2 receptor agonist and other t-cell activating agents

Info

Publication number
IL141627A0
IL141627A0 IL14162799A IL14162799A IL141627A0 IL 141627 A0 IL141627 A0 IL 141627A0 IL 14162799 A IL14162799 A IL 14162799A IL 14162799 A IL14162799 A IL 14162799A IL 141627 A0 IL141627 A0 IL 141627A0
Authority
IL
Israel
Prior art keywords
activation
cells
protection
receptor agonist
cell activating
Prior art date
Application number
IL14162799A
Other languages
English (en)
Original Assignee
Maxim Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharm Inc filed Critical Maxim Pharm Inc
Publication of IL141627A0 publication Critical patent/IL141627A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL14162799A 1998-08-24 1999-08-24 Activation and protection of t-cells (cd4+and cd8+) using an h2 receptor agonist and other t-cell activating agents IL141627A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13928198A 1998-08-24 1998-08-24
PCT/US1999/019211 WO2000010600A2 (fr) 1998-08-24 1999-08-24 Activation et protection de cellules t (cd4?+ et cd8+¿) a l'aide d'un agoniste du recepteur h¿2? et d'autres agents activant les cellules t

Publications (1)

Publication Number Publication Date
IL141627A0 true IL141627A0 (en) 2002-03-10

Family

ID=22485908

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14162799A IL141627A0 (en) 1998-08-24 1999-08-24 Activation and protection of t-cells (cd4+and cd8+) using an h2 receptor agonist and other t-cell activating agents

Country Status (11)

Country Link
US (1) US20030039628A1 (fr)
EP (1) EP1107784A2 (fr)
JP (1) JP2002523378A (fr)
KR (1) KR20010072957A (fr)
CN (1) CN1217698C (fr)
AU (1) AU765625C (fr)
CA (1) CA2341742A1 (fr)
IL (1) IL141627A0 (fr)
TW (1) TW576745B (fr)
WO (1) WO2000010600A2 (fr)
ZA (1) ZA200101787B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
AU2001282717A1 (en) 2000-07-28 2002-02-13 Cancer Research Technology Limited Cancer treatment by combination therapy
US20020094323A1 (en) 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
CN1608204A (zh) * 2001-12-21 2005-04-20 东弗吉尼亚医学院 分析药物效果的方法
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
EP1603567A4 (fr) * 2003-02-28 2006-10-18 Inotek Pharmaceuticals Corp Derives de benzamide tetracyclique et leurs procedes d'utilisation
WO2005023293A1 (fr) * 2003-09-09 2005-03-17 Pohang University Of Science And Technology Composition de vaccin comprenant un adjuvant d'il-12 encapsule dans une microsphere a liberation controlee
CA2557547A1 (fr) * 2004-02-26 2005-09-09 Inotek Pharmaceuticals Corporation Derives d'isoquinoline et methodes d'utilisation
EP1722796A4 (fr) * 2004-02-26 2008-01-23 Inotek Pharmaceuticals Corp Derives de lactame tetracyclique et utilisations
CA2571001A1 (fr) * 2004-06-16 2006-01-26 Inotek Pharmaceuticals Corporation Methodes de traitement ou de prevention de la dysfonction erectile ou de l'incontinence urinaire
US20060079510A1 (en) * 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
EP1850848A4 (fr) * 2005-02-25 2008-02-20 Inotek Pharmaceuticals Corp Composes tetracycliques de sulfonamide et methodes d'utilisation desdits composes
JP2008531562A (ja) * 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション 四環アミノ化合物および四環カルボキサミド化合物およびこれらの使用法
MX2007010335A (es) * 2005-02-25 2007-11-06 Inotek Pharmaceuticals Corp Compuestos de isoquinolina y metodos de uso de los mismos.
KR100735081B1 (ko) * 2005-04-21 2007-07-06 고려대학교 산학협력단 Ｃｄ4 ｔ 세포 활성화 방법
KR100735083B1 (ko) * 2005-04-21 2007-07-06 고려대학교 산학협력단 Ｃｄ8 ｔ 세포 활성화 방법
EP1937268A4 (fr) * 2005-08-24 2009-07-22 Inotek Pharmaceuticals Corp Analogues d'indenoisoquinolinone et leurs procedes d'utilisation
FR2903311B1 (fr) * 2006-07-10 2012-06-15 Centre Nat Rech Scient Utilisation de ligands du recepteur h4 de l'histamine pour proteger les progeniteurs hematopoietiques contre la toxicite hematologique des agents chimiotherapeutiques
JP2010520220A (ja) * 2007-02-28 2010-06-10 イノテック ファーマシューティカルズ コーポレイション インデノイソキノリノン類似体およびその使用方法
RU2499043C1 (ru) * 2012-09-26 2013-11-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Стимулятор пролиферации регуляторных т-лимфоцитов и способ их стимуляции
CL2013001774A1 (es) * 2013-06-18 2014-08-01 Univ Santiago Chile Formulacion con actividad inmunoestimulante/adyuvante que comprende alpinona , dimetil sulfóxido y suero fisiológico; uso de dicha formulación para preparar vacunas para vertebrados.
US20160256388A1 (en) * 2015-03-05 2016-09-08 Uri Galili Compositions and methods for treatment of respiratory tract infections
CN115894595B (zh) * 2021-09-30 2024-04-30 山东新时代药业有限公司 一种10,19-开环环阿屯烷三萜i及其制备方法和应用
CN115894601A (zh) * 2021-09-30 2023-04-04 山东新时代药业有限公司 一种10,19-开环环阿屯烷三萜ii及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025240A2 (fr) * 1992-06-09 1993-12-23 Neorx Corporation Procedes et composes de preciblage
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
CA2066728C (fr) * 1989-09-19 2001-12-25 Jan K. Hellstrand Preparation anti-tumorale composee d'interleukine-2 et d'histamine, leurs analogues ou agonistes des recepteurs h2
SE513429C2 (sv) * 1992-06-03 2000-09-11 Syntello Inc Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer
JPH10504304A (ja) * 1994-08-08 1998-04-28 マキシム ファーマシューティカルズ，インコーポレイテッド ナチュラルキラー細胞活性化物質と過酸化水素スカベンジャーまたは過酸化水素阻害物質とを用いるナチュラルキラー細胞の活性増強
GB9416657D0 (en) * 1994-08-17 1994-10-12 Biocine Spa T cell activation
WO1997030174A1 (fr) * 1996-02-20 1997-08-21 Sloan-Kettering Institute For Cancer Research Combinaison d'inhibiteurs de la proteine kinase c et agents therapeutiques pour traiter des cancers
ATE437366T1 (de) * 1998-05-11 2009-08-15 Miltenyi Biotec Gmbh Verfahren zur direkten auswahl von antigen- spezifischen t-zellen

Also Published As

Publication number Publication date
WO2000010600A3 (fr) 2000-06-15
CA2341742A1 (fr) 2000-03-02
WO2000010600A2 (fr) 2000-03-02
KR20010072957A (ko) 2001-07-31
EP1107784A2 (fr) 2001-06-20
ZA200101787B (en) 2001-09-27
WO2000010600A9 (fr) 2001-11-22
TW576745B (en) 2004-02-21
CN1217698C (zh) 2005-09-07
AU5687099A (en) 2000-03-14
CN1324245A (zh) 2001-11-28
JP2002523378A (ja) 2002-07-30
US20030039628A1 (en) 2003-02-27
AU765625C (en) 2004-11-18
AU765625B2 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
IL141627A0 (en) Activation and protection of t-cells (cd4+and cd8+) using an h2 receptor agonist and other t-cell activating agents
HUP0201545A3 (en) Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them
IL139136A0 (en) Il-2 selective agonists and antagonists
AU7464998A (en) Melanocortin receptor ligands and methods of using same
IL122022A0 (en) Adapter and signal transmission cable for mobile telephone
GB2326358B (en) Improved positioning device for concave of cone crusher
IL138576A0 (en) A novel interleukin-1 receptor antagonist and uses thereof
IL142164A0 (en) Cytokine receptor zalpha11
GB2327559B (en) Multifunction earphone microphone device
EP1023269A4 (fr) Agonistes de beta3-adrenorecepteurs, compositions d'agonistes et procedes d'utilisation
EP0838471A4 (fr) Derives peptidiques et agoniste du recepteur de l'angiotensine iv
AU5861900A (en) Receptor agonists and antagonists
GB9820014D0 (en) Receptor antagonists and uses thereof
AU2002347532A1 (en) Combination of an adenosine a2a receptor agonist and an adrenergic beta-2 receptor agonist
GB9827709D0 (en) Portable voice messaging and warning device
HUP9902824A3 (en) T-cell selective interleukin-4 agonists
AU9602198A (en) Cytoplasmic dipeptidylpeptidase iv from human t-cells
AU6125096A (en) C5a receptor antagonists having substantially no agonist activity and methods for preparation
AU4725599A (en) Human thyrotropin receptor compositions and use thereof
AU3425999A (en) Pharmaceutical compositions containing in combination an arginine-vasopressin v 1a antagonist and an angiotensin II at 1 receptor antagonist
GB9928566D0 (en) Human vanilloid receptor-like receptor
GB9615396D0 (en) Device for generating seismic shear waves
IL124550A0 (en) Compositions comprising activated t-cells or t-cell activating agents and their use
AU4064000A (en) Glucocorticoid receptor agonist and decreased pp5
AU8073198A (en) Telephone line testing device and equipment protector